Shots:

• Synaffix to receive upfront- milestone and royalty payments tied to each program while ADC gets a non-exclusive right for two additional programs- bringing the total number of programs to five
• ADC also get access to Synaffix’ GlycoConnect platform- including DAR1 technology enabling stable attachment of just a single drug per antibody
• In 2016- the two companies collaborated- under which ADC Therapeutics is responsible for the research- development- manufacturing- and commercialization of any resulting ADC products while Synaffix is responsible for the manufacturing of components specifically related to its ADC technologies

  Ref: Businesswire | Image: Synaffix